Literature DB >> 16513108

Effects of mu, kappa or delta opioids administered by pellet or pump on oral Salmonella infection and gastrointestinal transit.

Pu Feng1, Rahil T Rahim, Alan Cowan, Lee-Yuan Liu-Chen, Xiaohui Peng, John Gaughan, Joseph J Meissler, Martin W Adler, Toby K Eisenstein.   

Abstract

Our laboratory has shown previously that subcutaneously implanted, slow-release morphine pellets markedly enhanced susceptibility to oral infection with Salmonella typhimurium. Further, morphine, kappa and delta opioid receptor agonists infused via osmotic minipumps were immunosuppressive. The present study compared morphine pellets to morphine pumps and also examined the differential effects of morphine versus U50,488H (kappa agonist), deltorphin II (delta2 agonist), and (D-Pen2, D-Pen5)-enkephalin (DPDPE, delta1 agonist), administered via Alzet minipumps, on oral Salmonella infection and on gastrointestinal transit. The results show that all morphine-pelleted mice (26/26) had a marked increase in Salmonella burden in the Peyer's Patches, mesenteric lymph nodes and spleen. In comparison, only 8/20 mice receiving morphine by minipump at doses ranging from 1 to 25 mg/kg/day had any culturable Salmonella in their organs and the number of bacteria was very low. The level of Salmonella colonization correlated with blood morphine levels and gut transit measured using an intragastric charcoal meal. Morphine pellets inhibited gut transit by 38%, while mice receiving morphine by minipump at doses of 1 to 25 mg/kg/day showed only a dose-dependent 7% to 17% inhibition. Mice receiving various doses of U50,488H or DPDPE had no culturable Salmonella in the three sites. Deltorphin II given by minipump resulted in a moderate level of Salmonella in the spleen. Deltorphin II and U50,488H (0.1 to 10 mg/kg/day) did not suppress gut transit. The present studies indicate that a predominantly mu opioid receptor agonist, morphine, given by slow-release pellet, potentiated Salmonella infection and inhibited gastrointestinal transit. In contrast, morphine in pumps slightly inhibited intestinal transit, but did not sensitize to Salmonella infection. A delta1 opioid receptor agonist did not sensitize to infection, and a delta2 and a kappa opioid receptor agonist had minimal effects on either parameter.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16513108     DOI: 10.1016/j.ejphar.2006.01.048

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  22 in total

Review 1.  Opioids and HIV/HCV infection.

Authors:  Xu Wang; Ting Zhang; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-14       Impact factor: 4.147

Review 2.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

3.  Morphine, but not trauma, sensitizes to systemic Acinetobacter baumannii infection.

Authors:  Jessica M Breslow; M Alexandra Monroy; John M Daly; Joseph J Meissler; John Gaughan; Martin W Adler; Toby K Eisenstein
Journal:  J Neuroimmune Pharmacol       Date:  2011-08-09       Impact factor: 4.147

Review 4.  Molecular Pharmacology of δ-Opioid Receptors.

Authors:  Louis Gendron; Catherine M Cahill; Mark von Zastrow; Peter W Schiller; Graciela Pineyro
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

5.  Potentiating effect of morphine on oral Salmonella enterica serovar Typhimurium infection is μ-opioid receptor-dependent.

Authors:  Jessica M Breslow; Pu Feng; Joseph J Meissler; John E Pintar; John Gaughan; Martin W Adler; Toby K Eisenstein
Journal:  Microb Pathog       Date:  2010-08-03       Impact factor: 3.738

6.  Inflammation-associated changes in DOR expression and function in the mouse colon.

Authors:  Jesse J DiCello; Ayame Saito; Pradeep Rajasekhar; Emily M Eriksson; Rachel M McQuade; Cameron J Nowell; Benjamin W Sebastian; Jakub Fichna; Nicholas A Veldhuis; Meritxell Canals; Nigel W Bunnett; Simona E Carbone; Daniel P Poole
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-06-21       Impact factor: 4.052

7.  In vivo mapping of a GPCR interactome using knockin mice.

Authors:  Jade Degrandmaison; Khaled Abdallah; Véronique Blais; Samuel Génier; Marie-Pier Lalumière; Francis Bergeron; Catherine M Cahill; Jim Boulter; Christine L Lavoie; Jean-Luc Parent; Louis Gendron
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-26       Impact factor: 11.205

8.  Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons.

Authors:  Sylvia Fitting; Ruqiang Xu; Cecilia Bull; Shreya K Buch; Nazira El-Hage; Avindra Nath; Pamela E Knapp; Kurt F Hauser
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

Review 9.  Current overview of opioids in progression of inflammatory bowel disease; pharmacological and clinical considerations.

Authors:  Naser-Aldin Lashgari; Nazanin Momeni Roudsari; Nadia Zandi; Benyamin Pazoki; Atiyeh Rezaei; Mehrnoosh Hashemi; Saeideh Momtaz; Roja Rahimi; Maryam Shayan; Ahmad Reza Dehpour; Amir Hossein Abdolghaffari
Journal:  Mol Biol Rep       Date:  2021-01-04       Impact factor: 2.316

10.  Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer.

Authors:  Tamara King; Anna Vardanyan; Lisa Majuta; Ohannes Melemedjian; Ray Nagle; Anne E Cress; Todd W Vanderah; Josephine Lai; Frank Porreca
Journal:  Pain       Date:  2007-08-15       Impact factor: 6.961

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.